- Home
- INVE vs AVTX Comparison
INVE vs AVTX Comparison
Compare INVE & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INVE
- AVTX
- Stock Information
- Founded
- INVE 1990
- AVTX 2011
- Country
- INVE United States
- AVTX United States
- Employees
- INVE N/A
- AVTX N/A
- Industry
- INVE Computer peripheral equipment
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- INVE Technology
- AVTX Health Care
- Exchange
- INVE Nasdaq
- AVTX Nasdaq
- Market Cap
- INVE 85.9M
- AVTX 248.3M
- IPO Year
- INVE 1997
- AVTX 2015
- Fundamental
- Price
- INVE $3.84
- AVTX $14.92
- Analyst Decision
- INVE Strong Buy
- AVTX Strong Buy
- Analyst Count
- INVE 2
- AVTX 9
- Target Price
- INVE $5.50
- AVTX $30.14
- AVG Volume (30 Days)
- INVE 43.4K
- AVTX 357.3K
- Earning Date
- INVE 11-10-2025
- AVTX 11-06-2025
- Dividend Yield
- INVE N/A
- AVTX N/A
- EPS Growth
- INVE N/A
- AVTX N/A
- EPS
- INVE 3.12
- AVTX N/A
- Revenue
- INVE $23,538,000.00
- AVTX $192,000.00
- Revenue This Year
- INVE N/A
- AVTX N/A
- Revenue Next Year
- INVE $9.06
- AVTX N/A
- P/E Ratio
- INVE $1.22
- AVTX N/A
- Revenue Growth
- INVE N/A
- AVTX N/A
- 52 Week Low
- INVE $2.86
- AVTX $3.39
- 52 Week High
- INVE $4.29
- AVTX $19.41
- Technical
- Relative Strength Index (RSI)
- INVE 51.80
- AVTX 47.20
- Support Level
- INVE $3.71
- AVTX $15.81
- Resistance Level
- INVE $4.00
- AVTX $17.11
- Average True Range (ATR)
- INVE 0.20
- AVTX 1.54
- MACD
- INVE -0.01
- AVTX -0.44
- Stochastic Oscillator
- INVE 52.08
- AVTX 18.13
About INVE Identiv Inc.
Identiv Inc is a security technology company. It secures and manages access to physical places, things, and information. The company has one reportable segment: the IoT Business segment. Geographically, it generates maximum revenue from the Americas and also has a presence in Europe and the Middle East, and Asia-Pacific.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).